EC Number   |
Reference |
|---|
   3.2.2.23 | expressed in Escherichia coli BL21(DE3) cells |
716394, 716836 |
| 3.2.2.23 | expressed in Escherichia coli Rosetta (DE3) pLysS cells |
731705 |
| 3.2.2.23 | expressed in Escherichia coli strain BH540 |
716392 |
| 3.2.2.23 | expressed in HEK-293 cells |
732941 |
| 3.2.2.23 | expressed NCI-H727 non small cell lung carcinoma cells |
732781 |
| 3.2.2.23 | expression in Escherichia coli |
682591, 750688 |
| 3.2.2.23 | expression in human bladder cell |
680213 |
| 3.2.2.23 | expression of C-terminally His-tagged wild-type NEIL3 in Escherichia coli, and expression of the C-terminally His-tagged glycosylase domain of Neil3, MmuNeil3DELTA324, in an Escherichia coli triple mutant lacking Fpg, Nei, and MutY glycosylase activities, the recombinant MmuNeil3 greatly reduced both the spontaneous mutation frequency and the level of FapyG in the DNA |
710435 |
| 3.2.2.23 | expression of EGFP-tagged enzyme in HEK-293T cells. Transformation of primary human fibroblasts of a Cockayne syndrome patient using SV40, expression of FPG in 5-hydroxy-2'-deoxycytidine repair defective human cells complements the disorder and leads to stable correction of the delayed removal of both oxidized purines and oxidized pyrimidines in the cells, detailed overview |
708566 |
| 3.2.2.23 | expression of K155A mutant and wild-type Fpg in Escherichia coli BL21(DE3) and BLR(DE3) |
646945 |
